115 related articles for article (PubMed ID: 31259550)
1. Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T
Jackson JJ; Ketcham JM; Younai A; Abraham B; Biannic B; Beck HP; Bui MHT; Chian D; Cutler G; Diokno R; Hu DX; Jacobson S; Karbarz E; Kassner PD; Marshall L; McKinnell J; Meleza C; Okal A; Pookot D; Reilly MK; Robles O; Shunatona HP; Talay O; Walker JR; Wadsworth A; Wustrow DJ; Zibinsky M
J Med Chem; 2019 Jul; 62(13):6190-6213. PubMed ID: 31259550
[TBL] [Abstract][Full Text] [Related]
2. CCR4 Antagonists Inhibit T
Ketcham JM; Marshall LA; Talay O
ACS Med Chem Lett; 2018 Oct; 9(10):953-955. PubMed ID: 30344896
[TBL] [Abstract][Full Text] [Related]
3. Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.
Robles O; Jackson JJ; Marshall L; Talay O; Chian D; Cutler G; Diokno R; Hu DX; Jacobson S; Karbarz E; Kassner PD; Ketcham JM; McKinnell J; Meleza C; Reilly MK; Riegler E; Shunatona HP; Wadsworth A; Younai A; Brockstedt DG; Wustrow DJ; Zibinsky M
J Med Chem; 2020 Aug; 63(15):8584-8607. PubMed ID: 32667798
[TBL] [Abstract][Full Text] [Related]
4. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
5. A CCR4 antagonist enhances DC activation and homing to the regional lymph node and shows potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment.
Yamamoto S; Matsuo K; Nagakubo D; Higashiyama S; Nishiwaki K; Oiso N; Kawada A; Yoshie O; Nakayama T
J Pharmacol Sci; 2018 Mar; 136(3):165-171. PubMed ID: 29519579
[TBL] [Abstract][Full Text] [Related]
6. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
[TBL] [Abstract][Full Text] [Related]
7. FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer.
Sarkar T; Dhar S; Chakraborty D; Pati S; Bose S; Panda AK; Basak U; Chakraborty S; Mukherjee S; Guin A; Jana K; Sarkar DK; Sa G
Front Immunol; 2022; 13():740588. PubMed ID: 35222362
[TBL] [Abstract][Full Text] [Related]
8. Frequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma.
Lou H; Fang J; Li P; Zhou W; Wang Y; Fan E; Li Y; Wang H; Liu Z; Xiao L; Wang C; Zhang L
PLoS One; 2015; 10(5):e0126463. PubMed ID: 26020249
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.
Gobert M; Treilleux I; Bendriss-Vermare N; Bachelot T; Goddard-Leon S; Arfi V; Biota C; Doffin AC; Durand I; Olive D; Perez S; Pasqual N; Faure C; Ray-Coquard I; Puisieux A; Caux C; Blay JY; Ménétrier-Caux C
Cancer Res; 2009 Mar; 69(5):2000-9. PubMed ID: 19244125
[TBL] [Abstract][Full Text] [Related]
10. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.
Bayry J; Tchilian EZ; Davies MN; Forbes EK; Draper SJ; Kaveri SV; Hill AV; Kazatchkine MD; Beverley PC; Flower DR; Tough DF
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10221-6. PubMed ID: 18621704
[TBL] [Abstract][Full Text] [Related]
11. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.
Iellem A; Mariani M; Lang R; Recalde H; Panina-Bordignon P; Sinigaglia F; D'Ambrosio D
J Exp Med; 2001 Sep; 194(6):847-53. PubMed ID: 11560999
[TBL] [Abstract][Full Text] [Related]
12. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
13. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer.
Maeda S; Murakami K; Inoue A; Yonezawa T; Matsuki N
Cancer Immunol Res; 2019 Jul; 7(7):1175-1187. PubMed ID: 31160277
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effects of a novel CC chemokine receptor 4 antagonist on Th2 cell trafficking in ligand- and antigen-induced mouse models.
Komiya T; Sugiyama T; Takeda K; Watanabe N; Imai M; Kokubo M; Tokuda N; Ochiai H; Habashita H; Shibayama S
Eur J Pharmacol; 2013 Nov; 720(1-3):335-43. PubMed ID: 24140571
[TBL] [Abstract][Full Text] [Related]
15. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer.
Maeda S; Motegi T; Iio A; Kaji K; Goto-Koshino Y; Eto S; Ikeda N; Nakagawa T; Nishimura R; Yonezawa T; Momoi Y
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131860
[TBL] [Abstract][Full Text] [Related]
16. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
18. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.
Ishida T; Ishii T; Inagaki A; Yano H; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Res; 2006 Jun; 66(11):5716-22. PubMed ID: 16740709
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
[TBL] [Abstract][Full Text] [Related]
20. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.
Berlato C; Khan MN; Schioppa T; Thompson R; Maniati E; Montfort A; Jangani M; Canosa M; Kulbe H; Hagemann UB; Duncan AR; Fletcher L; Wilkinson RW; Powles T; Quezada SA; Balkwill FR
J Clin Invest; 2017 Mar; 127(3):801-813. PubMed ID: 28134623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
